Literature DB >> 30006767

Targeting the Neuromuscular Junction in ALS.

James Wymer1, David R Borchelt2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30006767      PMCID： PMC6095781          DOI： 10.1007/s13311-018-0647-y

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN： 1878-7479            Impact factor:   7.620


× No keyword cloud information.
  4 in total

1.  Neuroleptics as therapeutic compounds stabilizing neuromuscular transmission in amyotrophic lateral sclerosis.

Authors:  Shunmoogum A Patten; Dina Aggad; Jose Martinez; Elsa Tremblay; Janet Petrillo; Gary Ab Armstrong; Alexandre La Fontaine; Claudia Maios; Meijiang Liao; Sorana Ciura; Xiao-Yan Wen; Victor Rafuse; Justin Ichida; Lorne Zinman; Jean-Pierre Julien; Edor Kabashi; Richard Robitaille; Lawrence Korngut; J Alexander Parker; Pierre Drapeau
Journal:  JCI Insight       Date:  2017-11-16

2.  Increasing Evidence for an Association Between Amyotrophic Lateral Sclerosis and Psychiatric Disorders.

Authors:  Miguel Chuquilin; Susan Wymer; James Wymer
Journal:  JAMA Neurol       Date:  2017-12-01       Impact factor: 18.302

Review 3.  Neuromuscular junction destruction during amyotrophic lateral sclerosis: insights from transgenic models.

Authors:  Luc Dupuis; Jean-Philippe Loeffler
Journal:  Curr Opin Pharmacol       Date:  2009-04-20       Impact factor: 5.547

4.  Chronic Administration of Pimozide Fails to Attenuate Motor and Pathological Deficits in Two Mouse Models of Amyotrophic Lateral Sclerosis.

Authors:  Silvia Pozzi; Sai Sampath Thammisetty; Jean-Pierre Julien
Journal:  Neurotherapeutics       Date:  2018-07       Impact factor: 7.620
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.